Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs NSAIDs for inflammatory knee osteoarthritis
ChiCTR2300070156Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in knee osteoarthritis (OA) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: OMERACT-OARSI clinical response criteria, Erythrocyte sedimentation rate (ESR) and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2300070156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070156.